Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links
PHARMA - MEDICARE PROGRAM

Guidant alerts on flaw in pacemakers 

 

BY OUR PHARMA  CORRESPONDENT

19 July, 2005: The Indianapolis-based Guidant Corporation issued an alert to doctors that some of the patients using its pacemakers might need to have the units replaced as nine of its older pacemaker models were prone to failing.

The alert covers 28,000 pacemakers made from November 1997 to October 2000 and still implanted in patients. Guidant said that a component used to seal the pacemakers could degrade, allowing moisture to build up and causing the devices to fail. Such failure could cause "serious health complications" in some patients, the company said. 

The company is already embroiled in controversy over recall tens of thousands of implantable heart defibrillators in recent weeks.

A statement from US FDA said the agency was aware that Guidant had issued the pacemaker alert to doctors and that it was evaluating the matter. Guidant said it expected the FDA to designate the alert as a recall, a formal classification that involves the type of physician notification that Guidant is already making.

A recall does not mean that a device should be removed. Instead, patients are typically advised to discuss with their doctors the risk posed by a device compared with the risk posed by the surgical procedure needed to replace it. 

The nine older pacemaker models are involved are the Pulsar Max, the Pulsar, the Discovery, the Meridian, the Pulsar Max II, the Discovery II, the Virtus Plus II, the Intellis II and the Contak TR. The units, which are of an earlier design, have not been implanted for the last four years, the company said.

Guidant said it had identified 69 devices that may have had the seal problem, out of some 78,000 devices in which that component was used. Currently, about 28,000 of those units are still implanted in patients, with 18,000 of them in the United States.

In 20 known cases, the problem caused pacemakers to fail, and in 5 such instances, patients blacked out, apparently because of inadequate blood flow. In two other instances, the flaw may have caused a pacemaker to keep pacing at a high rate.

In one such case, that flaw may have contributed to a patient's death. However, because the unit was not returned to Guidant for inspection, the company said it was not clear if the death was related to the device or to the patient's health problems. 

Guidant Corporation develops, manufactures and markets products including coronary stent systems, dilatation catheters, intravascular radiotherapy systems and related accessories, implantable defibrillator systems, implantable pacemaker systems, angioplasty systems, cardiac surgery systems, implantable cardiac resynchronization therapy. The group has principal operations in the United States, Europe, Asia and Japan.

Guidant's recent spate of recalls is likely to play a role in discussions of second-quarter earnings results due this week from both Guidant and Johnson & Johnson, which agreed in December to buy Guidant for $25.4 billion.

 

Pharma News Headlines

Cancer News

Cardiac News

US FDA News

Pharma industry news

LATEST UPDATES

Roche, Novartis lead on novel cancer therapies

US FDA grants fast track status for GSK’s HIV drug

Stem Cell Bill could be delayed in US

FDA warning on abortion drug Mifeprex (Mifepristone)

US FDA recalls Baxter’s intravenous pumps

US FDA grants tentative nod to Ranbaxy’s glimepiride

Lupin launches generic ceftriaxone in US

Hormonal contraceptives safe for long-term use: WHO

Abortion pill to carry 'black box' warning

Vaccines not linked to autism, say experts

Novartis acquires Bristol-Myers’ OTC business in US

Guidant alerts on flaw in pacemakers

Awareness on Medicare drug benefit scheme low in US

NIH review finds govt scientists having ties with pharma firms

US FDA to decide on Plan B morning-after pill by Sept 1

Painkiller patch Duragesic under US FDA probe over patients deaths

Legionnaire's disease outbreak in US hospital in New Rochelle 

Genepharm in pact with 3 Australian distributors 

UK has new generics reimbursement scheme 

Teva gets US FDA nod for mirtazapine anti-depressant 

US patent office rejects Pfizer’s Lipitor claims 

Aethlon Medical to start trials on HIV device in India 

Panel to decide fate of Advair, Serevent and Foradil asthma drugs 

Prohibitive costs mar cancer therapy 

FDA directs Palladone withdrawal

Blindness alert on impotence drugs  

Novartis files for breast cancer drug in US, Europe  

Merck readies for $10 billion Vioxx battle  

Speak up on menopause, campaign urges US women 

Direct-To-Consumer ads mislead patients: US Senator  

EU to decide on sops for developing kids drugs  

Zidovudine by Ranbaxy gets US FDA tentative nod

Parkinson's Disease therapy triggers gambling in some patients

Parkinson's Disease symptoms may be relieved by Azilect

Are obesity and diabetes just accelerated aging?

Reducing lung infection and inflammation due to Cystic Fibrosis

Viruses may help cure cancer by killing cancer cells

New product relieves tooth pain resulting from dental sensitivity 

Cervical Cancer detector may improve on Pap Smears

Dietary supplement capsule by Liqing banned in US

Cold Stone Creamery cake batter ice-creams recalled

Guidant defibrillator recall: US FDA makes three classifications

AIDS drug stavudine by Aurobindo Pharma gets tentative US FDA approval for PEPFAR

Gates Foundation donates for a good cause

Paxil CR resupply in US pharmacies announced by GlaxoSmithKline

Viagra users not at risk of blindness: Pfizer

Stem cell research gets boost from Li Ka-shing

BiDil heart failure drug for black patients approved

Restless leg syndrome could be messing up your sleep

Glaxo Smithkline in pact with IAVI to develop AIDS drug

Pfizer acquires Vicuron Pharma for $1.9 billion

German Remedies launches Fludara Oral

Ranbaxy acquires generic product portfolio from Efarmes

Sandoz files seven ANDAs of drugs going off-patent

Elder Pharma plans unit, brand acquisition

Novasite Pharma buys PsyCheNomicS

Chemokine gets US patent for novel cancer drug

Roche gets USFDA approval for oral Xeloda

Nectar Lifesciences plans Rs 90 crore IPO 

Glaxo inks co-promotion pact with Eisai for Paritec

Early Intervention required to Prevent Diabetes

AIDS drug ahoy!

Novartis launches AMD patient counselling programme

Nanobac Life Sciences, UCSF to study kidney stones 

Surface Logix commences phase I trial for PDE-5 inhibitor

Temasek sets up $112 million pharma JV

Contraceptive from Neem, courtesy DRDO  

US FDA to source anti-HIV drugs from Indian firms  

Chemists boycott Glaxo, Novartis products  

Maharashtra phases out nerve tissue-based rabies vaccine  

Last long, really long - new sex drug soon  

Johnson and Johnson demonstrates coronary stent safety

Novartis has better breast cancer treatment

Pfizer's investigational drug reduces tumor growth

New labeling for beta-blocker Coreg 

Glaxo applies for FDA approval for Flaurix

Investigational drug for Acute Bipolar Mania And Schizophrenia

Preclinical Data Support Link Between IL-9 and Airway Hyperresponsiveness Associated With Asthma

 

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us